Physician profile
Clayton Mann Macconnell
NPI 1891767794
$2,490.15
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $101 · 2021: $540 · 2022: $752 · 2023: $413 · 2024: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.48 | 2021-2024 | |
| Zealand Pharma US, INC. | $236.94 | 2020-2021 | |
| Valeritas, INC. | $232.78 | 2019 | |
| Novo Nordisk INC | $187.96 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $180.01 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $156.62 | 2021-2023 | |
| Beta Bionics, INC. | $132.21 | 2023 | Ilet Bionic Pancreas |
| Mannkind Corporation | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.36 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $73.36 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $66.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.81 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $58.84 | 2022-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $54.34 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $50.78 | 2024 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Macconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.